Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
new york top stories
97
×
new york blog main
life sciences
boston blog main
national top stories
boston top stories
san francisco blog main
san francisco top stories
biotech
san diego blog main
san diego top stories
wisconsin blog main
wisconsin top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
detroit blog main
detroit top stories
texas blog main
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
fda
clinical trials
deals
startups
cancer
pfizer
gene therapy
novartis
amgen
merck
bristol-myers squibb
eli lilly
regeneron pharmaceuticals
What
drug
roundup
bio
new
fda
medicine
medicines
cancer
medical
week
companies
drugs
ipo
approved
patients
biotech
deal
life
therapy
days
disease
gene
science
big
long
nash
news
pharmaceutical
annual
approval
based
ceo
cholesterol
conference
help
latest
moves
plan
prices
therapeutics
Language
unset
unknown
Current search:
" new york top stories "
×
@xconomy.com
4 months ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
5 months ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
5 months ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 months ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
6 months ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
7 months ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
8 months ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
9 months ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
10 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
11 months ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
11 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
1 year ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
1 year ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
1 year ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
1 year ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
1 year ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com
1 year ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
1 year ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
1 year ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
1 year ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
1 year ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
1 year ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
1 year ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
1 year ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
1 year ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
1 year ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
1 year ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
1 year ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
1 year ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
1 year ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
1 year ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
1 year ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
1 year ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com
1 year ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
1 year ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
1 year ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com
1 year ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
1 year ago
Review: Inside the House of Lies at Theranos
@xconomy.com
1 year ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
1 year ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
1 year ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
1 year ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
First
Prev
Page 1
(current)
Next
Last